 |
|
Clinical Trial of Photodynamic Therapy With Meso-Tetra (Hydroxyphenyl) Chlorin for Respiratory Papillomatosis
Mark J. Shikowitz, MD;
Allan L. Abramson, MD;
Bettie M. Steinberg, PhD;
James DeVoti, PhD;
Vincent R. Bonagura, MD;
Virginia Mullooly, RN, MS;
May Nouri, MS;
Avigdor M. Ronn, PhD;
Andrew Inglis, MD;
John McClay, MD;
Kathrine Freeman, DrPH
Arch Otolaryngol Head Neck Surg. 2005;131:99-105.
Objective To determine the efficacy of photodynamic therapy (PDT) with meso-tetra (hydroxyphenyl) chlorin (m-THPC) photosensitizer for recurrent respiratory papillomatosis.
Design Parallel-arm, randomized trial of patients requiring surgery at least 3 times yearly with single PDT 6 or 18 months after enrollment and 12-month follow-up. Disease extent was scored and papillomas were removed during direct endoscopy every 3 months after enrollment.
Setting Tertiary medical centers.
Patients Of 23 patients aged 4 to 60 years enrolled in the study, 15 patients, plus 2 in the late group without PDT owing to airway risk, completed the study. Six patients withdrew voluntarily after PDT.
Intervention Intravenous administration of m-THPC 6 days before direct endoscopic PDT with 80 to 100 J of light for adults and 60 to 80 J for children.
Main Outcome Measures Difference in severity scores between the early and late groups and between pre- and post-PDT scores for all patients. Secondary measures were the associations between baseline characteristics and response and changes in immune response and the prevalence of latent viral DNA.
Results There were significant differences between groups, with marked improvement in laryngeal disease across time after PDT (P = .006). Five of 15 patients were in remission 12 to 15 months after treatment, but there was recurrence of disease after 3 to 5 years. Tracheal disease was not responsive to PDT. No change occurred in the prevalence of latent human papillomavirus DNA. The immune response to virus improved with clinical response.
Conclusions Use of m-THPC PDT reduces the severity of laryngeal papillomas, possibly through an improved immune response. Failure to maintain remission with time suggests that this is not an optimal treatment.
Author Affiliations: Departments of Otolaryngology and Communicative Disorders (Drs Shikowitz, Abramson, Steinberg, and Ronn and Mss Mullooly and Nouria) and Pediatrics (Drs DeVoti and Bonagura), Long Island Jewish Medical Center and Schneider’s Children’s Hospital, and Institute for Medical Research, North Shore–Long Island Jewish Health System (Drs Steinberg, DeVoti, and Bonagura and Ms Nouri), New Hyde Park, NY; Department of Otolaryngology, Children’s Hospital and Regional Medical Center, Seattle, Wash (Dr Inglis); Department of Otolaryngology, Southwestern Medical Center, Dallas, Tex (Dr McClay); and Department of Epidemiology and Social Medicine, Biostatistics, Montefiore Medical Center of the Albert Einstein College of Medicine, Bronx, NY (Dr Freeman).
|
